Anixa Biosciences, a company that focuses on cancer treatment and prevention, has announced that its partner, Cleveland Clinic, has been given an “Intention to Grant” notice from the European Patent Office for the patent application titled “Ovarian Cancer Vaccines.” This is fantastic news for the company as it extends protection for their ovarian cancer vaccine technology to additional potential markets.
The late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic are the inventors of the patented technology. Anixa exclusively licensed the technology from Cleveland Clinic and is partnering with them to develop the treatment. The National Cancer Institute is also involved through its PREVENT program.
Their ovarian cancer vaccine targets AMHR2-ED, a protein that is expressed in most ovarian cancers. This is a significant breakthrough in cancer research and has the potential to make a real impact in the field of oncology.
Anixa Biosciences is a clinical-stage biotechnology company that specialises in cancer treatment and prevention. Their ovarian cancer immunotherapy program, developed in collaboration with Moffitt Cancer Center, uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company also has a vaccine portfolio, which includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent triple negative breast cancer (TNBC), as well as a vaccine to prevent ovarian cancer. These advancements show promise in immunizing against proteins that have been found to be expressed in certain forms of cancer.
The company’s unique business model of partnering with world-renowned research institutions on clinical development allows them to continuously explore emerging technologies in the field of cancer treatment and commercialization.
It’s always encouraging to see companies invest in research and development efforts in areas that directly impact people’s lives. By focusing their efforts on cancer treatment and prevention, Anixa Biosciences is making a significant contribution to the medical community.
The announcement about the European patent is just one of the many achievements Anixa has made. It shows their commitment to advancing cancer research. It’s a step forward as they continue to develop and enhance their portfolio of cancer treatment technologies.
For more information about Anixa Biosciences, you can visit their website at www.anixa.com or follow them on Twitter, LinkedIn, Facebook, and YouTube.
In conclusion, securing the European patent for their ovarian cancer vaccine technology is a significant accomplishment for Anixa Biosciences. It not only validates their commitment to cancer research but also opens the doors to potential markets in Europe. This breakthrough has the potential to make a real impact in the field of oncology and improve the lives of cancer patients around the world.
+ There are no comments
Add yours